ReviewInternational journal of molecular sciences2019
Intestinal Microbiota: A Novel Target to Improve Anti-Tumor Treatment?
Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- The role of the microbiome in uterine cancer: insights into tumorigenesis, therapeutic implications, and clinical prospects.Journal of the Egyptian National Cancer Institute · 2026Review
- Microbiome in Gastrointestinal Tumors: Implications in Oncogenesis and Therapeutic Response : Microbiome in Gastrointestinal Tumors.Current oncology reports · 2026Review
- Microbiomics: Novel Biomarkers of Colorectal Cancer Diagnosis and Prognosis.Diagnostics (Basel, Switzerland) · 2026Review
- Gut Microbiota: A Potential Role in Modulating Carcinogenesis and Response to Anti-Cancer Therapies.Cancer reports (Hoboken, N.J.) · 2026Review
- Assessing mental health, cognitive function and quality of life of breast cancer patients: exploring associations with gut microbiota in an observational and preliminary study.Frontiers in psychology · 2026Article
- Lipid Metabolism Reprogramming in Cancer: Insights into Tumor Cells and Immune Cells Within the Tumor Microenvironment.Biomedicines · 2025Review
- Harnessing the Microbiome: CRISPR-Based Gene Editing and Antimicrobial Peptides in Combating Antibiotic Resistance and Cancer.Probiotics and antimicrobial proteins · 2025Review
- Analysis of gastric mucosa associated microbiota in functional dyspepsia using 16S rRNA gene next-generation sequencing.BMC microbiology · 2025Article
- Metaproteomics in the One Health framework for unraveling microbial effectors in microbiomes.Microbiome · 2025Review
- Bacillus coagulans 198 and L-glutamine in combination attenuated intestinal mucositis in a 5-FU-induced BALB/c mouse model via modulation of gut microbial community structure and diversity.Journal of food and drug analysis · 2025Article
- The Role of the Gut Microbiota in Modulating Signaling Pathways and Oxidative Stress in Glioma Therapies.Cancers · 2025Review
- Research Progress with Atractylone as an Antitumor Agent.Molecules (Basel, Switzerland) · 2024Review
- Revealing the therapeutic properties of gut microbiota: transforming cancer immunotherapy from basic to clinical approaches.Medical oncology (Northwood, London, England) · 2024Review
- Acute Impacts of Ionizing Radiation Exposure on the Gastrointestinal Tract and Gut Microbiome in Mice.International journal of molecular sciences · 2024Article
- The potential role of gut microbiota in the occurrence and development of endometriosis.Frontiers in cellular and infection microbiology · 2024Article
- Targeting the gut microbiota to enhance the antitumor efficacy and attenuate the toxicity of CAR-T cell therapy: a new hope?Frontiers in immunology · 2024Review
- Gut virome dysbiosis impairs antitumor immunity and reduces 5-fluorouracil treatment efficacy for colorectal cancer.Frontiers in oncology · 2024Article
- 2,5-dimethylcelecoxib alleviated NK and T-cell exhaustion in hepatocellular carcinoma via the gastrointestinal microbiota-AMPK-mTOR axis.Journal for immunotherapy of cancer · 2023Article
- The Influence of the Microbiome on Metastatic Colorectal Cancer.Clinics in colon and rectal surgery · 2023Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Recently, preclinical and clinical studies targeting several types of cancer strongly supported the key role of the gut microbiota in the modulation of host response to anti-tumoral therapies such as chemotherapy, immunotherapy, radiotherapy and even surgery. Intestinal microbiome has been shown to participate in the resistance to a wide range of anticancer treatments by direct interaction with the treatment or by indirectly stimulating host response through immunomodulation. Interestingly, these effects were described on colorectal cancer but also in other types of malignancies. In addition to their role in therapy efficacy, gut microbiota could also impact side effects induced by anticancer treatments. In the first part of this review, we summarized the role of the gut microbiome on the efficacy and side effects of various anticancer treatments and underlying mechanisms. In the second part, we described the new microbiota-targeting strategies, such as probiotics and prebiotics, antibiotics, fecal microbiota transplantation and physical activity, which could be effective adjuvant therapies developed in order to improve anticancer therapeutic efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.